These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2070282)

  • 1. Why measurement of apoB helps in the diagnosis and treatment of atherogenic dyslipoproteinemias.
    Sniderman A
    Can J Cardiol; 1991 May; 7(4):VII-VIII. PubMed ID: 2070282
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis].
    Cabezas Castro M; Liem A
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1445-8. PubMed ID: 12908345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipoproteinemias after heart and heart-lung transplantation: potential relation to accelerated graft arteriosclerosis.
    Bilodeau M; Fitchett DH; Guerraty A; Sniderman AD
    J Heart Transplant; 1989; 8(6):454-9. PubMed ID: 2614546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A1 and B.
    Sniderman AD; Marcovina SM
    Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effective diagnosis and treatment of atherosclerosis. Canadian Cardiovascular Society.
    Frohlich JJ
    Can J Cardiol; 1995 May; 11 Suppl C():41C-42C. PubMed ID: 7750050
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current approaches to the diagnosis and correction of atherogenic dyslipoproteinemia].
    Oganov RG; Perova NV
    Kardiologiia; 1989 Oct; 29(10):15-22. PubMed ID: 2615152
    [No Abstract]   [Full Text] [Related]  

  • 7. [Is hypolipemic treatment effective as a preventive measure?].
    Rywik S
    Przegl Lek; 1989; 46(7):619-23. PubMed ID: 2685917
    [No Abstract]   [Full Text] [Related]  

  • 8. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
    de Graaf J; Couture P; Sniderman A
    Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):608-18. PubMed ID: 18838971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study.
    Holme I; Høstmark AT; Anderssen SA
    J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 11. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hyperlipoproteinemia in the production of atherosclerosis. Risk factors: diagnosis and treatment].
    Pedraza A
    Rev Fac Cien Med Univ Nac Cordoba; 1993; 51(1):21-33. PubMed ID: 7809452
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperapobetalipoproteinaemia: an emerging risk factor for atherosclerosis.
    Thompson GR; Trayner IA; Allaway SL; Robinson D; Ritchie CD
    Monogr Atheroscler; 1986; 14():129-31. PubMed ID: 3736551
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of antiatherogenic L-aspartate and L-glutamate on serum lipoproteins cholesterol and apolipoproteins A-1 and B in rabbits fed with high cholesterol diet.
    Yanni AE; Perrea DN; Yatzidis HA
    Nutr Metab Cardiovasc Dis; 2005 Jun; 15(3):161-5. PubMed ID: 15955463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: implications for atherogenic risk.
    Lowry RP; Soltys G; Peters L; Mangel R; Sniderman AD
    Transplant Proc; 1987 Aug; 19(4):3426-30. PubMed ID: 3303510
    [No Abstract]   [Full Text] [Related]  

  • 16. Apolipoproteins as markers and managers of coronary risk.
    Chan DC; Watts GF
    QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. If apoB is so good, why isn't everybody measuring it? One reason why we need The Netherlands Journal of Medicine!
    Sniderman AD; Rosenbloom M
    Neth J Med; 2005 Jun; 63(6):232-5. PubMed ID: 16011018
    [No Abstract]   [Full Text] [Related]  

  • 18. [The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis].
    Kravchenko NA
    Tsitol Genet; 1995; 29(4):84-7. PubMed ID: 8604528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).
    Williams K; Sniderman AD; Sattar N; D'Agostino R; Wagenknecht LE; Haffner SM
    Circulation; 2003 Nov; 108(19):2312-6. PubMed ID: 14581403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.